Hypha Labs (FUNI) 10-K 27 Dec 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2018	Dec. 25, 2018	Mar. 31, 2018
Document And Entity Information
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	1,502,966
Document Type	10-K
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 8,120,756
Entity Common Stock, Shares Outstanding		43,257,277
Trading Symbol	DIGP
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Current assets:
Cash	$ 176,027	$ 178,177
Accounts receivable	167,734	266,613
Prepaid expenses	72,690	73,750
Deposits	25,647	25,647
Total current assets	442,098	544,187
Fixed assets, net	957,108	1,027,049
Total Assets	1,399,206	1,571,236
Current liabilities:
Accounts payable	325,864	121,994
Accrued expenses	58,238	42,004
Deferred revenues	525
Total current liabilities	384,627	163,998
Total Liabilities	384,627	163,998
Stockholders' Equity:
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 1,425,942 and 1,897,942 shares issued and outstanding at September 30, 2018 and 2017, respectively	1,426	1,898
Common stock, $0.001 par value, 90,000,000 shares authorized; 42,245,364 and 35,027,118 shares issued and outstanding at September 30, 2018 and 2017, respectively	42,245	35,027
Additional paid-in capital	14,121,236	12,866,984
Accumulated (deficit)	(13,150,328)	(11,496,671)
Total Stockholders' Equity	1,014,579	1,407,238
Total Liabilities and Stockholders' Equity	$ 1,399,206	$ 1,571,236

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Sep. 30, 2017
Statement of Financial Position [Abstract]
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000	10,000,000
Series A convertible preferred stock, shares issued	1,425,942	1,897,942
Series A convertible preferred stock, shares outstanding	1,425,942	1,897,942
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	90,000,000	90,000,000
Common stock, shares issued	42,245,364	35,027,118
Common stock, shares outstanding	42,245,364	35,027,118

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenues	$ 2,839,916	$ 1,898,172
Cost of sales	2,069,837	904,166
Gross profit	770,079	994,006
Operating expenses:
General and administrative	1,451,642	1,257,745
Professional fees	1,094,486	1,001,289
Bad debts expense (recoveries)	(17,280)	32,180
Total operating expenses	2,528,848	2,291,214
Operating loss	(1,758,769)	(1,297,208)
Other income:
Other income	105,112	282,068
Loss on impairment of securities available-for-sale		(50,000)
Total other income	105,112	232,068
Net loss	$ (1,653,657)	$ (1,065,140)
Weighted average number of common shares outstanding - basic and fully diluted	39,079,547	29,321,193
Net loss per share - basic and fully diluted	$ (0.04)	$ (0.04)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated (Deficit) [Member]	Total
Balance at Sep. 30, 2016	$ 3,520	$ 22,491	$ 11,681,282	$ (40,800)	$ (10,431,531)	$ 1,234,962
Balance, shares at Sep. 30, 2016	3,520,442	22,491,041
Units of common stock and warrants sold for cash		$ 3,499	557,001			560,500
Units of common stock and warrants sold for cash, shares		3,498,577
Common stock issued for services		$ 925	245,455			246,380
Common stock issued for services, shares		925,000
Common stock options issued for services			389,736			389,736
Conversion of preferred stock to common stock	$ (1,622)	$ 8,112	(6,490)
Conversion of preferred stock to common stock, shares	(1,622,500)	8,112,500
Realized loss on available-for-sale securities				40,800		40,800
Net loss					(1,065,140)	(1,065,140)
Balance at Sep. 30, 2017	$ 1,898	$ 35,027	12,866,984		(11,496,671)	1,407,238
Balance, shares at Sep. 30, 2017	1,897,942	35,027,118
Units of common stock and warrants sold for cash		$ 2,159	366,449			368,608
Units of common stock and warrants sold for cash, shares		2,158,934
Common stock issued for services		$ 2,327	450,210			452,537
Common stock issued for services, shares		2,326,855
Common stock options issued for services			439,853			439,853
Conversion of preferred stock to common stock	$ (472)	$ 2,360	(1,888)
Conversion of preferred stock to common stock, shares	(472,000)	2,360,000
Cashless exercise of options and warrants		$ 372	(372)
Cashless exercise of options and warrants, shares		372,457
Net loss					(1,653,657)	(1,653,657)
Balance at Sep. 30, 2018	$ 1,426	$ 42,245	$ 14,121,236		$ (13,150,328)	$ 1,014,579
Balance, shares at Sep. 30, 2018	1,425,942	42,245,364

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities
Net loss	$ (1,653,657)	$ (1,065,140)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	(17,280)	32,180
Depreciation and amortization expense	277,294	253,535
Stock issued for services	452,537	246,380
Options and warrants granted for services	439,853	389,736
Realized loss on available-for-sale securities		50,000
Decrease (increase) in assets:
Accounts receivable	116,159	(200,352)
Prepaid expenses	1,060	(49,504)
Deposits		14,203
Increase (decrease) in liabilities:
Accounts payable	203,870	(35,672)
Accrued expenses	16,234	(12,243)
Deferred revenues	525
Net cash used in operating activities	(163,405)	(376,877)
Cash flows from investing activities
Purchase of fixed assets	(207,353)	(140,836)
Net cash used in investing activities	(207,353)	(140,836)
Cash flows from financing activities
Proceeds from sale of common stock	368,608	560,500
Net cash provided by financing activities	368,608	560,500
Net increase (decrease) in cash	(2,150)	42,787
Cash - beginning	178,177	135,390
Cash - ending	176,027	178,177
Supplemental disclosures:
Interest paid
Income taxes paid
Non-cash investing and financing activities:
Value of preferred stock converted to common stock	$ 472,000	$ 1,622,500

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2018: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Reclassifications Prior period interest income in the amount of $10,000 has been reclassified to net against the related $10,000 of bad debt expense to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $14,900 and $32,180 as of September 30, 2018 and 2017, respectively. Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Revenue Recognition Effective October 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements from ASC 606 for the years ended September 30, 2018 or 2017 since it was not adopted until October 1, 2018. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. The Company also recognizes revenue through our subsidiary, TNM News Corp., which primarily recognizes revenue from advertisements through partnered merchants. Payment for ad revenues are received prior to the distribution of the ad campaign, and the revenues are recognized ratably over the campaign. The Company defers any revenue for which the term of the campaign has not yet been realized. To date, these revenues have not been materially significant. Deferred revenues on advertisement campaigns was $525 at September 30, 2018. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $108,295 and $138,026 for the years ended September 30, 2018 and 2017, respectively. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2018 and 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. Recent Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of ($13,150,328), and as of September 30, 2018, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Stock Issued to Officers for Services On September 25, 2018, we issued 39,344 shares of common stock to our Chief Executive Officer, Todd Denkin, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On September 25, 2018, we issued 98,361 shares of common stock to our Chief Financial Officer, Todd Peterson, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On June 25, 2018, we issued 118,421 shares of common stock to our then Chief Executive Officer, Joseph Bianco, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $22,500 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On June 25, 2018, we issued 31,579 shares of common stock to our Chief Executive Officer, Todd Denkin, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On June 25, 2018, we issued 78,947 shares of common stock to our Chief Financial Officer, Todd Peterson, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 26, 2018, we issued 207,852 shares of common stock to our then Chief Executive Officer, Joseph Bianco, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $45,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 26, 2018, we issued 55,427 shares of common stock to our Chief Executive Officer, Todd Denkin, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $12,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On March 26, 2018, we issued 138,568 shares of common stock to our Chief Financial Officer, Todd Peterson, for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $30,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 22, 2017, we issued 300,000 shares of common stock to our Chief Financial Officer, Todd Peterson, as a bonus for services rendered. The aggregate fair value of the common stock was $78,828 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. Stock Issued to Directors for Services On September 12, 2018, we issued 200,000 shares of common stock to Bruce Raben in connection with his appointment to our Board of Directors. The aggregate fair value of the common stock was $31,020 based on the closing price of the Company’s common stock on the date of grant, and is to be expensed over the requisite service period through September 30, 2019. A total of $1,458 was expensed during the year ended September 30, 2018, and as of September 30, 2018, a total of $29,562 of unamortized expenses are expected to be expensed during the fiscal year ended September 30, 2019. On December 22, 2017, we issued 100,000 shares of common stock to Dr. Alfredo Axtmayer for his service on our Board of Directors. The aggregate fair value of the common stock was $26,276 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. Options Issued to Officers and Directors for Services On September 12, 2018, we granted options to purchase 200,000 shares of common stock as compensation for services to our Chief Science Officer pursuant to her appointment to the Company’s Board of Directors. The options vest over a one-year period and are exercisable for a ten-year period at an exercise price of $0.16 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1245, was $24,905. The options are being expensed over the vesting period, resulting in $1,170 of stock-based compensation expense during the year ended September 30, 2018. As of September 30, 2018, options to purchase 200,000 shares of common stock remained unvested and a total of $23,735 of unamortized expense is expected to be expensed during the fiscal year ended September 30, 2019. On December 22, 2017, we granted fully vested options to purchase 500,000 shares of common stock as compensation for services to our Chief Executive Officer, Todd Denkin. The options are exercisable over a ten-year period at an exercise price of $0.27 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 112% and a call option value of $0.2094, was $104,698, which was expensed on the grant date, resulting in $104,698 of stock-based compensation expense during the year ended September 30, 2018.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 4 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2018 and 2017, respectively: Fair Value Measurements at September 30, 2018 Level 1 Level 2 Level 3 Assets Cash $ 176,027 $ - $ - Total assets 176,027 - - Liabilities None - - - Total liabilities - - - $ 176,027 $ - $ - Fair Value Measurements at September 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 178,177 $ - $ - Total assets 178,177 - - Liabilities None - - - Total liabilities - - - $ 178,177 $ - $ - The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2018 or 2017. We recognized other than temporary impairment losses of $50,000 on our available-for-sale securities during the year ended September 30, 2017.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Sep. 30, 2018
Receivables [Abstract]
Accounts Receivable	Note 5 – Accounts Receivable Accounts receivable was $167,734 and $266,613 at September 30, 2018 and 2017, respectively, net of allowance for uncollectible accounts of $14,900 and $32,180 at September 30, 2018 and 2017, respectively.

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 6 – Fixed Assets Fixed assets consist of the following at September 30, 2018 and 2017: For the Years Ended September 30, 2018 2017 Software $ 123,492 $ 121,617 Office equipment 54,877 36,080 Furniture and fixtures 28,486 14,285 Lab equipment 1,110,930 938,450 Leasehold improvements 489,147 489,147 1,806,932 1,599,579 Less: accumulated depreciation (849,824 ) (572,530 ) Total $ 957,108 $ 1,027,049 On October 1, 2016, we disposed of fixed assets with a net book value of $3,122 pursuant to the deconsolidation of Digipath Corp. The fixed assets consisted of furniture and fixtures with a historical cost basis of $48,779 and software with a historical cost basis of $10,019, and accumulated depreciation of $48,779 and $6,897, respectively. No gain or loss was recognized on the disposals. Depreciation and amortization expense totaled $277,294 and $253,535 for the years ended September 30, 2018 and 2017, respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity	Note 7 – Stockholders’ Equity Convertible Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”), with the remaining 4,000,000 shares available for designation from time to time by the Board as set forth below. As of September 30, 2018, there were 1,425,942 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which the undesignated shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Each share of Series A Preferred is currently convertible into five shares of common stock. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,425,942 shares of Series A Preferred outstanding at September 30, 2018 are convertible into 7,129,710 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series A Preferred plus all accrued but unpaid dividends. ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. The Series A Preferred generally will vote together with the common stock and not as a separate class, except as provided below. ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Preferred Stock Conversions for the Year Ended September 30, 2018 For the year ended September 30, 2018, a total of 472,000 shares of Series A Preferred were converted into 2,360,000 shares of common stock at a value of $0.20 per share of common stock, or a total of $472,000. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Preferred Stock Conversions for the Year Ended September 30, 2017 For the year ended September 30, 2017, a total of 1,622,500 shares of Series A Preferred were converted into 8,112,500 shares of common stock at a value of $0.20 per share of common stock, or a total of $1,622,500. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Common stock consists of $0.001 par value, 90,000,000 shares authorized, of which 42,245,364 shares were issued and outstanding as of September 30, 2018. Common Stock Sales for the Year Ended September 30, 2018 On July 11, 2018, the Company sold 66.67 units, consisting of 666,667 shares of its common stock and warrants to purchase 333,334 shares of common stock, exercisable at $0.30 per share over a thirty-six month period, in exchange for total proceeds of $100,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 13, 2018, the Company sold 14 units, consisting of an aggregate of 140,000 shares of its common stock and warrants to purchase 70,000 shares of common stock, exercisable at $0.30 per share over a thirty-six month period, in exchange for total proceeds of $25,200. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 12, 2018, the Company sold 28 units, consisting of an aggregate of 280,000 shares of its common stock and warrants to purchase 140,000 shares of common stock, exercisable at $0.30 per share over a thirty-six month period, in exchange for total proceeds of $50,400. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On April 10, 2018, the Company sold 27.78 units, consisting of an aggregate of 277,778 shares of its common stock and warrants to purchase 138,889 shares of common stock, exercisable at $0.30 per share over a thirty-six month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On December 20, 2017, the Company sold 10 units, consisting of an aggregate of 100,000 shares of its common stock and warrants to purchase 50,000 shares of common stock, exercisable at $0.26 per share over a thirty-six month period, in exchange for total proceeds of $18,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On December 14, 2017, the Company sold 13.89 units, consisting of an aggregate of 138,889 shares of its common stock and warrants to purchase 69,445 shares of common stock, exercisable at $0.26 per share over a thirty-six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On December 14, 2017, the Company sold 55.56 units, consisting of an aggregate of 555,600 shares of its common stock and warrants to purchase 277,800 shares of common stock, exercisable at $0.26 per share over a thirty-six month period, in exchange for total proceeds of $100,008. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. Common Stock Sales for the Year Ended September 30, 2017 On August 25, 2017, the Company sold 33.333 units, consisting of 333,334 shares of its common stock and warrants to purchase 166,667 shares of common stock, exercisable at $0.26 per share over a sixty month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On August 25, 2017, the Company sold 7 units, consisting of 70,000 shares of its common stock and warrants to purchase 35,000 shares of common stock, exercisable at $0.30 per share over a sixty month period, in exchange for total proceeds of $10,500. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On August 4, 2017, the Company sold 100 units, consisting of 1,000,000 shares of its common stock and warrants to purchase 500,000 shares of common stock, exercisable at $0.26 per share over a sixty month period, in exchange for total proceeds of $150,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On July 28, 2017, the Company sold 33.333 units, consisting of 333,334 shares of its common stock and warrants to purchase 166,667 shares of common stock, exercisable at $0.26 per share over a sixty month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On June 21, 2017, the Company sold 33.333 units, consisting of 333,334 shares of its common stock and warrants to purchase 166,667 shares of common stock, exercisable at $0.26 per share over a sixty month period, in exchange for total proceeds of $50,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On February 21, 2017, the Company sold 1,428,575 units, consisting of 1,428,575 shares of its common stock and warrants to purchase 714,285 shares of common stock, exercisable at $0.26 per share over a thirty-six month period, in exchange for total proceeds of $250,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. The warrants were assigned to two individuals by the purchaser at the time of the sale. Exercise of Options for the Year Ended September 30, 2018 On January 3, 2018, two option holders exercised options to purchase a total of 500,000 shares of common stock at $0.181 per share on a cashless basis, resulting in the issuance of 317,172 shares of common stock. On January 2, 2018, an option holder exercised options to purchase 37,500 shares of common stock at $0.22 per share on a cashless basis, resulting in the issuance of 21,000 shares of common stock. Exercise of Warrants for the Year Ended September 30, 2018 On January 3, 2018, a warrant holder exercised warrants to purchase 71,428 shares of common stock at $0.26 per share on a cashless basis, resulting in the issuance of 34,285 shares of common stock. Additional Common Stock Issuances for the Year Ended September 30, 2018 On September 25, 2018, the Company issued 39,344 shares of common stock to its President and CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On September 25, 2018, the Company issued 98,361 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On September 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $22,875 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On September 12, 2018, the Company issued 193,424 shares of common stock to another consultant for business development services. The fair value of the common stock was $30,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On September 12, 2018, the Company issued 200,000 shares of common stock to Bruce Raben in connection with his appointment to our Board of Directors. The aggregate fair value of the common stock was $31,020 based on the closing price of the Company’s common stock on the date of grant, and is to be expensed over the requisite service period through September 30, 2019. A total of $1,458 was expensed during the year ended September 30, 2018, and as of September 30, 2018, a total of $29,562 of unamortized expenses are expected to be expensed during the fiscal year ended September 30, 2019. On June 25, 2018, the Company issued 118,421 shares of common stock to its then CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $22,500 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On June 25, 2018, the Company issued 31,579 shares of common stock to its then President and COO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On June 25, 2018, the Company issued 78,947 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On June 25, 2018, the Company issued 131,579 shares of common stock to a consultant for business development services. The fair value of the common stock was $25,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On June 25, 2018, the Company issued 100,000 shares of common stock to another consultant for business development services. The fair value of the common stock was $19,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On March 26, 2018, the Company issued 207,852 shares of common stock to its then CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $45,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On March 26, 2018, the Company issued 55,427 shares of common stock to its then President and COO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $12,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On March 26, 2018, the Company issued 138,568 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $30,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On March 26, 2018, the Company issued 69,284 shares of common stock to a consultant for business development services. The fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. On December 22, 2017, the Company issued 300,000 shares of common stock to its CFO as a bonus for services rendered. The aggregate fair value of the common stock was $78,828 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On December 22, 2017, the Company issued 100,000 shares of common stock to Dr. Alfredo Axtmayer for his service on our Board of Directors. The aggregate fair value of the common stock was $26,276 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On November 29, 2017, a total of 314,069 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $82,600 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2018. Additional Common Stock Issuances for the Year Ended September 30, 2017 On May 2, 2017, the Company issued 100,000 shares of common stock to Dr. John Abroon in connection with his appointment to our newly created Advisory Board. The aggregate fair value of the common stock was $20,900 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On May 2, 2017, the Company issued 140,000 shares of common stock to a consultant in consideration of services rendered from April 1, 2017 through May 31, 2017. The aggregate fair value of the common stock was $29,260 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On March 1, 2017, the Company issued 25,000 shares of common stock to its CFO as a bonus for services rendered. The aggregate fair value of the common stock was $6,623 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On March 1, 2017, the Company issued 50,000 shares of common stock to its Chief Scientist as a bonus for services rendered. The aggregate fair value of the common stock was $13,245 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 23, 2017, the Company issued 100,000 shares of common stock to a consultant for services to be rendered over a six month period. The aggregate fair value of the common stock was $29,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2017. On February 22, 2017, the Company issued 100,000 shares of common stock to Dr. Alfredo Axtmayer in connection with his appointment to our Board of Directors. The aggregate fair value of the common stock was $34,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 22, 2017, the Company issued 40,000 shares of common stock to a consultant for services rendered. The aggregate fair value of the common stock was $13,600 based on the closing price of the Company’s common stock on the date of grant, and was expensed in full. On February 7, 2017, a total of 370,000 shares of common stock were issued to six consultants that were engaged to assist the Company with acquisition activities over a six month period. The aggregate fair value of the common stock was $82,251 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period that ended on September 30, 2017.

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock Options	Note 8 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. Options to purchase a total of 8,537,500 shares of common stock were outstanding as of September 30, 2018 Common Stock Option Issuances for the Year Ended September 30, 2018 On September 12, 2018, we granted options to purchase 200,000 shares of common stock as compensation for services to our Chief Science Officer pursuant to her appointment to the Company’s Board of Directors. The options vest over a one-year period, are exercisable over a ten-year period at an exercise price of $0.16 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1245, was $24,905. The options are being expensed over the vesting period, resulting in $1,170 of stock-based compensation expense during the year ended September 30, 2018. As of September 30, 2018, options to purchase 200,000 shares of common stock remained unvested and a total of $23,735 of unamortized expenses are expected to be expensed during the fiscal year ended September 30, 2019. On December 22, 2017, we granted fully vested options to purchase 500,000 shares of common stock as compensation for services to our then President and COO. The options are exercisable over a ten-year period at an exercise price of $0.27 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 112% and a call option value of $0.2094, was $104,698. The options were expensed over the vesting period, resulting in $104,698 of stock-based compensation expense during the year ended September 30, 2018. On November 29, 2017, we granted fully vested options to purchase 100,000 shares of common stock as compensation for services to our Chief Scientist. The options are exercisable over a ten-year period at an exercise price of $0.27 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 112% and a call option value of $0.21, was $21,004. The options were expensed over the vesting period, resulting in $21,004 of stock-based compensation expense during the year ended September 30, 2018. On November 29, 2017, we granted fully vested options to purchase an aggregate of 205,000 shares of common stock as compensation for services to a total of ten of our employees. The options are exercisable over a ten-year period at an exercise price of $0.27 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 112% and a call option value of $0.21, was $43,057. The options were expensed over the vesting period, resulting in $43,057 of stock-based compensation expense during the year ended September 30, 2018. Common Stock Options Exercised for the Year Ended September 30, 2018 On January 3, 2018, two option holders exercised options to purchase a total of 500,000 shares of common stock at $0.181 per share on a cashless basis, resulting in the issuance of 317,172 shares of common stock. On January 2, 2018, an option holder exercised options to purchase 37,500 shares of common stock at $0.22 per share on a cashless basis, resulting in the issuance of 21,000 shares of common stock. Common Stock Options Cancelled or Expired for the Year Ended September 30, 2018 During the year ended September 30, 2018, options to purchase an aggregate of 110,000 shares of common stock, exercisable over a ten-year period, at a weighted average exercise price of $0.25 per share expired. During the year ended September 30, 2018, options to purchase an aggregate of 1,110,000 shares of common stock, exercisable over a three-year period, at a weighted average exercise price of $0.44 per share expired. Common Stock Options Cancelled or Expired for the Year Ended September 30, 2017 On January 1, 2017, a total of 1,530 common stock options exercisable over a three-year period from the original grant date of January 1, 2014 with an exercise price of $3.30 per share expired. The following is a summary of information about the stock options outstanding at September 30, 2018. Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $0.16 – $0.40 8,537,500 4.27 years $ 0.20 8,337,500 $ 0.21 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2018 2017 Average risk-free interest rates 1.36 % N/A % Average expected life (in years) 5.25 N/A Volatility 112 % N/A % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2018 and September 30, 2017, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2018 was approximately $0.25 per option. The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2016 9,291,530 $ 0.23 Options expired (1,530 ) (3.30 ) Balance, September 30, 2017 9,290,000 0.23 Options issued 1,005,000 0.25 Options exercised (537,500 ) (0.18 ) Options expired (1,220,000 ) (0.42 ) Balance, September 30, 2018 8,537,500 $ 0.20 Exercisable, September 30, 2018 8,337,500 $ 0.21 Amortization of Stock Options A total of $439,853 and $389,736 of stock-based compensation expense was recognized from the amortization of options over their vesting period during the years ended September 30, 2018 and 2017, respectively. As of September 30, 2018, these options in the aggregate had no intrinsic value as the per share market price of $0.15 of the Company’s common stock as of such date was less than the weighted-average exercise price of these options of $0.20.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Common Stock Warrants	Note 9 – Common Stock Warrants We issued warrants in connection with private placements of our securities as set forth in Note 8 above. On January 3, 2018 a warrant holder exercised warrants to purchase 71,428 shares of common stock at $0.26 per share on a cashless basis, resulting in the issuance of 34,285 shares of common stock. On December 31, 2017, warrants to purchase 200,000 shares of common stock at $0.30 per share expired, and on December 30, 2017, warrants to purchase another 300,000 shares of common stock at $0.45 per share also expired. The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2018 (including those issued to both investors and service providers). Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $0.1901 – $0.40 6,450,462 1.65 years $ 0.28 6,450,462 $ 0.28 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2018 2017 Average risk-free interest rates 1.56 % 1.11 % Average expected life (in years) 3.00 3.50 Volatility 110 % 145 % The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock during the years ended September 30, 2018 and 2017 was approximately $0.29 and $0.26 per warrant, respectively. The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2016 4,193,136 $ 0.29 Warrants granted 1,749,286 0.26 Balance, September 30, 2017 5,942,422 0.28 Warrants granted 1,079,468 0.29 Warrants exercised (71,428 ) (0.26 ) Warrants expired (500,000 ) (0.36 ) Balance, September 30, 2018 6,450,462 $ 0.28 Exercisable, September 30, 2018 6,450,462 $ 0.28

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 10 – Commitments and Contingencies Lease Commitment The Company leases space for its lab operations in Las Vegas, Nevada. Amounts of minimum future annual commitments on a calendar year basis, including common area maintenance fees, under non-cancelable operating leases are as follows: 2018 $ 48,872 2019 198,904 2020 151,283 2021 50,102 Total $ 449,161 Rent expense was $191,751 and $210,907 for the years ended September 30, 2018 and 2017, respectively.

Other Income

Other Income	12 Months Ended
	Sep. 30, 2018
Other Income and Expenses [Abstract]
Other Income	Note 11 – Other Income Other income for the years ended September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Settlement income on license agreement $ - $ 250,000 Rental income on subleases 76,800 20,568 Restitution income 28,312 11,500 $ 105,112 $ 282,068

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Tax	Note 12 - Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2018 and 2017, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2018, the Company had approximately $7,982,500 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The effective income tax rate for the years ended September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Federal statutory income tax rate 21 % 35 % State income taxes - % - % Change in valuation allowance (21 %) (35 %) Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: September 30, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,676,325 $ 2,531,725 Net deferred tax assets before valuation allowance $ 1,676,325 $ 2,531,725 Less: Valuation allowance (1,676,325 ) (2,531,725 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2018 and 2017, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events Debt Financing On November 8, 2018, the Company sold 8% Senior Secured Convertible Notes in the aggregate principal amount of $500,000 to two institutional investors. The Notes mature on December 31, 2020, bear interest at a rate of 8% per annum, and are convertible into shares of the Company’s common stock at a fixed conversion price of $0.14 per share. The Company’s obligation under the Notes are secured by a lien on the assets of the Company and its wholly-owned subsidiary Digipath Labs, Inc., pursuant to a Security Agreement between the Company, Digipath Labs, Inc. and the collateral agent for the investors. Common Stock Issued for Services On December 25, 2018, the Company issued 46,261 shares of common stock to its President and CEO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $6,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2018, the Company issued 115,652 shares of common stock to its CFO for services rendered pursuant to his employment agreement. The aggregate fair value of the common stock was $15,000 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On December 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $19,455 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On November 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $19,260 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. On October 30, 2018, the Company issued 400,000 shares of common stock to another consultant for business development services to be performed from November 1, 2018 through April 30, 2019. The fair value of the common stock was $54,120 based on the closing price of the Company’s common stock on the date of grant, and is being expensed over the requisite service period. On October 25, 2018, a total of 150,000 shares of common stock were issued to three consultants that were engaged to assist the Company with acquisition activities. The aggregate fair value of the common stock was $23,250 based on the closing price of the Company’s common stock on the date of grant, and was expensed over the requisite service period. Common Stock Option Issuances On December 25, 2018, we granted options to purchase an aggregate of 235,000 shares of common stock as compensation for services to a total of ten of our employees, vesting twelve months from the grant date. The options are exercisable over a ten-year period at an exercise price of $0.13 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 107% and a call option value of $0.1017, was $35,078. The options are to be expensed over the vesting period. Common Stock Warrants Expired On December 21, 2018, warrants to purchase 166,667 shares of common stock at $0.30 per share expired. On November 23, 2018, warrants to purchase another 100,000 shares of common stock at $0.40 per share also expired.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Nature of Business	Nature of Business Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our business units are described below. ● Digipath Labs, Inc ● The National Marijuana News Corp
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2018: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Reclassifications	Reclassifications Prior period interest income in the amount of $10,000 has been reclassified to net against the related $10,000 of bad debt expense to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $14,900 and $32,180 as of September 30, 2018 and 2017, respectively.
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements Term of lease Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. Our intellectual property is comprised of indefinite-lived brand names acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.
Revenue Recognition	Revenue Recognition Effective October 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. There was no impact on the Company’s financial statements from ASC 606 for the years ended September 30, 2018 or 2017 since it was not adopted until October 1, 2018. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. The Company also recognizes revenue through our subsidiary, TNM News Corp., which primarily recognizes revenue from advertisements through partnered merchants. Payment for ad revenues are received prior to the distribution of the ad campaign, and the revenues are recognized ratably over the campaign. The Company defers any revenue for which the term of the campaign has not yet been realized. To date, these revenues have not been materially significant. Deferred revenues on advertisement campaigns was $525 at September 30, 2018.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $108,295 and $138,026 for the years ended September 30, 2018 and 2017, respectively.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2018 and 2017, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In March 2018, the FASB issued ASU No. 2018-05, Income Taxes (Topic 740) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2018: State of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary TNM News, Inc. Nevada Subsidiary GroSciences, Inc. (3) Colorado Subsidiary (1) (2) (3)
Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment	The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements Term of lease

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2018 and 2017, respectively: Fair Value Measurements at September 30, 2018 Level 1 Level 2 Level 3 Assets Cash $ 176,027 $ - $ - Total assets 176,027 - - Liabilities None - - - Total liabilities - - - $ 176,027 $ - $ - Fair Value Measurements at September 30, 2017 Level 1 Level 2 Level 3 Assets Cash $ 178,177 $ - $ - Total assets 178,177 - - Liabilities None - - - Total liabilities - - - $ 178,177 $ - $ -

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2018 and 2017: For the Years Ended September 30, 2018 2017 Software $ 123,492 $ 121,617 Office equipment 54,877 36,080 Furniture and fixtures 28,486 14,285 Lab equipment 1,110,930 938,450 Leasehold improvements 489,147 489,147 1,806,932 1,599,579 Less: accumulated depreciation (849,824 ) (572,530 ) Total $ 957,108 $ 1,027,049

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2018. Shares Underlying Options Outstanding Shares Underlying Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $0.16 – $0.40 8,537,500 4.27 years $ 0.20 8,337,500 $ 0.21
Schedule of Option Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2018 2017 Average risk-free interest rates 1.36 % N/A % Average expected life (in years) 5.25 N/A Volatility 112 % N/A %
Summary of Common Stock Options Activity Outstanding	The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2016 9,291,530 $ 0.23 Options expired (1,530 ) (3.30 ) Balance, September 30, 2017 9,290,000 0.23 Options issued 1,005,000 0.25 Options exercised (537,500 ) (0.18 ) Options expired (1,220,000 ) (0.42 ) Balance, September 30, 2018 8,537,500 $ 0.20 Exercisable, September 30, 2018 8,337,500 $ 0.21

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at September 30, 2018 (including those issued to both investors and service providers). Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $0.1901 – $0.40 6,450,462 1.65 years $ 0.28 6,450,462 $ 0.28
Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan	The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2018 2017 Average risk-free interest rates 1.56 % 1.11 % Average expected life (in years) 3.00 3.50 Volatility 110 % 145 %
Summary of Common Stock Warrants Activity Outstanding	The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2016 4,193,136 $ 0.29 Warrants granted 1,749,286 0.26 Balance, September 30, 2017 5,942,422 0.28 Warrants granted 1,079,468 0.29 Warrants exercised (71,428 ) (0.26 ) Warrants expired (500,000 ) (0.36 ) Balance, September 30, 2018 6,450,462 $ 0.28 Exercisable, September 30, 2018 6,450,462 $ 0.28

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payment Under Operating Leases	2018 $ 48,872 2019 198,904 2020 151,283 2021 50,102 Total $ 449,161

Other Income (Tables)

Other Income (Tables)	12 Months Ended
	Sep. 30, 2018
Other Income and Expenses [Abstract]
Schedule of Other Income	Other income for the years ended September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Settlement income on license agreement $ - $ 250,000 Rental income on subleases 76,800 20,568 Restitution income 28,312 11,500 $ 105,112 $ 282,068

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The effective income tax rate for the years ended September 30, 2018 and 2017 consisted of the following: September 30, 2018 2017 Federal statutory income tax rate 21 % 35 % State income taxes - % - % Change in valuation allowance (21 %) (35 %) Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: September 30, 2018 2017 Deferred tax assets: Net operating loss carry forwards $ 1,676,325 $ 2,531,725 Net deferred tax assets before valuation allowance $ 1,676,325 $ 2,531,725 Less: Valuation allowance (1,676,325 ) (2,531,725 ) Net deferred tax assets $ - $ -

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative)	12 Months Ended
	Sep. 30, 2018USD ($)Segment	Sep. 30, 2017USD ($)
Number of reportable segment | Segment	1
Allowance for doubtful accounts receivable	$ 14,900	$ 32,180
Deferred revenues	525
Advertising and promotions expense	108,295	$ 138,026
Bad Debt [Member]
Prior period reclassification net value	10,000
Interest Income [Member]
Prior period reclassification net value	$ 10,000

Nature of Business and Signif_5

Nature of Business and Significant Accounting Policies - Schedule of Entities Under Common Control and Ownership (Details) - Entities Under Common Control and Ownership [Member]	12 Months Ended
	Sep. 30, 2018
Name of Entity	Digipath, Inc.	[1],[2]
State of Incorporation	Nevada	[2]
Relationship	Parent	[2]
Name of Entity	Digipath Labs, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	TNM News, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Name of Entity	GroSciences, Inc.	[1],[3]
State of Incorporation	Colorado	[3]
Relationship	Subsidiary	[3]
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above were wholly-owned by Digipath, Inc., the parent company.
[3]	Entity formed for prospective purposes, but has not incurred any income or expenses as of the end of the period.

Nature of Business and Signif_6

Nature of Business and Significant Accounting Policies - Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment (Details)	12 Months Ended
	Sep. 30, 2018
Software [Member]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	5 years
Lab Equipment [Member]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment Estimated Useful Lives	Term of lease

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (13,150,328)	$ (11,496,671)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 25, 2018	Sep. 12, 2018	Jun. 25, 2018	Mar. 26, 2018	Dec. 22, 2017	Feb. 22, 2017	Sep. 30, 2018	Sep. 30, 2017
Number of common stock issued for services							$ 452,537	$ 246,380
Fair value measurements, volatility rate							112.00%	0.00%
Todd Denkin [Member]
Number of common stock shares issued for services	39,344		31,579	55,427
Number of common stock issued for services	$ 6,000		$ 6,000	$ 12,000
Number of common stock shares compensation issued for services					500,000
Stock based compensation expense					$ 104,698		$ 104,698
Options exercisable description					The options are exercisable over a ten year period
Common stock exercise price					$ 0.27
Fair value measurements, volatility rate					112.00%
Call option value					$ 0.2094
Todd Peterson [Member]
Number of common stock shares issued for services	98,361		78,947	138,568	300,000
Number of common stock issued for services	$ 15,000		$ 15,000	$ 30,000	$ 78,828
Joseph Bianco [Member]
Number of common stock shares issued for services			118,421	207,852
Number of common stock issued for services			$ 22,500	$ 45,000
Bruce Raben [Member]
Number of common stock shares issued for services		200,000
Number of common stock issued for services		$ 31,020
Number of common stock shares compensation issued for services		200,000
Number of common stock shares compensation issued for services, value		$ 31,020
Stock based compensation expense							1,458
Unamortized expenses							29,562
Dr. Alfredo Axtmayer [Member]
Number of common stock shares issued for services					100,000	100,000
Number of common stock issued for services					$ 26,276	$ 34,000
Chief Science Officer [Member]
Number of common stock shares compensation issued for services		200,000
Stock based compensation expense							$ 1,170
Number of common stock remained unvested							200,000
Unamortized expenses							$ 23,735
Options exercisable description		The options vest over a one-year period and are exercisable for a ten-year period
Common stock exercise price		$ 0.16
Fair value measurements, volatility rate		107.00%
Call option value		$ 0.1245
Stock option expenses		$ 24,905

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Loss on impairment of securities available-for-sale		$ 50,000

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Level 1 [Member]
Cash	$ 176,027	$ 178,177
Total assets	176,027	178,177
Total liabilities
Total	176,027	178,177
Level 2 [Member]
Cash
Total assets
Total liabilities
Total
Level 3 [Member]
Cash
Total assets
Total liabilities
Total

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Receivables [Abstract]
Accounts receivable	$ 167,734	$ 266,613
Allowance for uncollectible accounts	$ 14,900	$ 32,180

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Oct. 02, 2016
Fixed assets book value			$ 3,122
Gain or loss recognized on disposals
Depreciation and amortization expense	$ 277,294	$ 253,535
Furniture and Fixtures [Member]
Fixed assets historical cost basis			48,779
Fixed assets accumulated depreciation and amortization			48,779
Software [Member]
Fixed assets historical cost basis			10,019
Fixed assets accumulated depreciation and amortization			$ 6,897

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Software	$ 123,492	$ 121,617
Office equipment	54,877	36,080
Furniture and fixtures	28,486	14,285
Lab equipment	1,110,930	938,450
Leasehold improvements	489,147	489,147
Fixed assets, gross	1,806,932	1,599,579
Less: accumulated depreciation	(849,824)	(572,530)
Total	$ 957,108	$ 1,027,049

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Sep. 25, 2018	Sep. 12, 2018	Jul. 11, 2018	Jun. 25, 2018	Apr. 13, 2018	Apr. 12, 2018	Apr. 10, 2018	Mar. 26, 2018	Jan. 03, 2018	Jan. 02, 2018	Dec. 22, 2017	Dec. 20, 2017	Dec. 14, 2017	Nov. 29, 2017	Aug. 25, 2017	Aug. 04, 2017	Jul. 28, 2017	Jun. 21, 2017	May 02, 2017	Mar. 01, 2017	Feb. 23, 2017	Feb. 22, 2017	Feb. 21, 2017	Feb. 07, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 30, 2017
Preferred stock, shares authorized																									10,000,000	10,000,000
Preferred stock, par value																									$ 0.001	$ 0.001
Preferred stock, shares issued																									1,425,942	1,897,942
Preferred stock, shares outstanding																									1,425,942	1,897,942
Common stock par value																									$ 0.001	$ 0.001
Common stock authorized																									90,000,000	90,000,000
Common stock, shares issued																									42,245,364	35,027,118
Common Stock, shares outstanding																									42,245,364	35,027,118
Number of common stock sold			66.67		14	28	27.78					10	13.89		33.333	100	33.333	33.333					1,428,575
Number of warrant to purchase of common stock shares									71,428																		200,000	300,000
Warrants exercise price per share									$ 0.26																$ 0.29	$ 0.26	$ 0.30	$ 0.45
Proceeds from sale of common stock																									$ 368,608	$ 560,500
Share issued in exercise stock option										37,500															537,500
Stock option exercise price per share										$ 0.22															$ 0.18
Common stock shares issued									34,285	21,000
Common stock issued for services																									$ 452,537	$ 246,380
Consultant One [Member]
Number of common stock issued for services				131,579
Common stock issued for services				$ 25,000
Consultant Two [Member]
Number of common stock issued for services				100,000
Common stock issued for services				$ 19,000
Holders [Member]
Percentage of equity beneficial ownership																									100.00%
President and CEO [Member]
Number of common stock issued for services	39,344
Common stock issued for services	$ 6,000
CFO [Member]
Number of common stock issued for services	98,361			78,947				138,568			300,000									25,000
Common stock issued for services	$ 15,000			$ 15,000				$ 30,000			$ 78,828									$ 6,623
Three Consultants [Member]
Number of common stock issued for services	150,000													314,069
Common stock issued for services	$ 22,875													$ 82,600
Another Consultants [Member]
Number of common stock issued for services		193,424
Common stock issued for services		$ 30,000
Bruce Raben [Member]
Number of common stock issued for services		200,000
Common stock issued for services		$ 31,020
Stock based compensation expense																									$ 1,458
Unamortized expenses																									29,562
Bruce Raben [Member] | September 30, 2019 [Member]
Unamortized expenses																									$ 29,562
CEO [Member]
Number of common stock issued for services				118,421				207,852
Common stock issued for services				$ 22,500				$ 45,000
COO [Member]
Number of common stock issued for services				31,579
Common stock issued for services				$ 6,000
President and COO [Member]
Number of common stock issued for services								55,427
Common stock issued for services								$ 12,000
Consultant [Member]
Number of common stock issued for services								69,284											140,000		100,000	40,000
Common stock issued for services								$ 15,000											$ 29,260		$ 29,000	$ 13,600
Dr. Alfredo Axtmayer [Member]
Number of common stock issued for services											100,000											100,000
Common stock issued for services											$ 26,276											$ 34,000
Dr. John Abroon [Member]
Number of common stock issued for services																			100,000
Common stock issued for services																			$ 20,900
Chief Scientist [Member]
Number of common stock issued for services																				50,000
Common stock issued for services																				$ 13,245
Six Consultants [Member]
Number of common stock issued for services																								370,000
Common stock issued for services																								$ 82,251
Common Stock [Member]
Number of common stock sold			666,667		140,000	280,000	277,778					100,000	138,889		333,334	1,000,000	333,334	333,334					1,428,575
Number of warrant to purchase of common stock shares			333,334		70,000	140,000	138,889					50,000	69,445		166,667	500,000	166,667	166,667					714,285
Warrants exercise price per share			$ 0.30		$ 0.30	$ 0.30	$ 0.30					$ 0.26	$ 0.26		$ 0.26	$ 0.26	$ 0.26	$ 0.26					$ 0.26
Proceeds from sale of common stock			$ 100,000		$ 25,200	$ 50,400	$ 50,000					$ 18,000	$ 25,000		$ 50,000	$ 150,000	$ 50,000	$ 50,000					$ 250,000
Number of common stock issued for services																									2,326,855	925,000
Common stock issued for services																									$ 2,327	$ 925
Common Stock Unit [Member]
Number of common stock sold													55.56		7
Common Stock One [Member]
Number of common stock sold													555,600		70,000
Number of warrant to purchase of common stock shares													277,800		35,000
Warrants exercise price per share													$ 0.26		$ 0.30
Proceeds from sale of common stock													$ 100,008		$ 10,500
Two Option Holder [Member]
Share issued in exercise stock option									500,000	37,500
Stock option exercise price per share									$ 0.181	$ 0.22
Common stock shares issued									317,172	21,000
Series A Convertible Preferred Stock [Member]
Preferred stock, shares designated																									6,000,000
Preferred stock, shares designated remaining																									4,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued																									1,425,942
Preferred stock, shares outstanding																									1,425,942
Preferred stock convertible into common stock shares																									7,129,710
Percentage of equity beneficial ownership																									4.99%
Stock conversion, shares converted																									472,000	1,622,500
Stock conversion, shares issued																									2,360,000	8,112,500
Stock conversion price per shares																									$ 0.20	$ 0.20
Stock conversion value																									$ 472,000	$ 1,622,500

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)	Sep. 12, 2018	Jan. 03, 2018	Jan. 02, 2018	Dec. 22, 2017	Nov. 29, 2017	Jan. 02, 2017	Jun. 21, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Number of options outstanding								8,537,500	9,290,000	9,291,530
Options exercise price per share								$ 0.25
Volatility rate								112.00%	0.00%
Common stock options exercised			37,500					537,500
Exercised option price per share			$ 0.22					$ 0.18
Common stock shares issued		34,285	21,000
Intrinsic value
Intrinsic value, market price per share								$ 0.15
Intrinsic value weighted-average exercise price per share								$ 0.20
Common Stock Option One [Member]
Options exercisable period								10 years
Common stock options cancelled or expired								110,000
Weighted average exercise price per share expired								$ 0.25
Common Stock Option Two [Member]
Options exercisable period								3 years
Common stock options cancelled or expired								1,110,000
Weighted average exercise price per share expired								$ 0.44
Common Stock Options [Member]
Options exercisable period						3 years
Common stock options cancelled or expired						1,530
Weighted average exercise price per share expired						$ 3.30
Amortization of Stock Options [Member]
Amortization of stock options								$ 439,853	$ 389,736
Two Option Holder [Member]
Common stock options exercised		500,000	37,500
Exercised option price per share		$ 0.181	$ 0.22
Common stock shares issued		317,172	21,000
Ten Employees [Member]
Options exercisable period					10 years
Options exercise price per share					$ 0.27
Volatility rate					112.00%
Call option value					$ 0.21
Fair value of stock options					$ 43,057
Stock based compensation expense								$ 43,057
Number of shares granted fully vested common stock option					205,000
Chief Science Officer [Member]
Options exercisable period	10 years
Number granted options to purchase shares of common stock	200,000							200,000
Options vesting term	1 year
Options exercise price per share	$ 0.16
Volatility rate	107.00%
Call option value	$ 0.1245
Fair value of stock options	$ 24,905
Stock based compensation expense								$ 1,170
Unamortized expenses expected to be expensed								23,735
President and Chief Operating Officer [Member]
Options exercisable period				10 years
Options exercise price per share				$ 0.27
Volatility rate				112.00%
Call option value				$ 0.2094
Fair value of stock options				$ 104,698
Stock based compensation expense								104,698
Number of shares granted fully vested common stock option				500,000
Chief Scientist [Member]
Options exercisable period					10 years
Options exercise price per share					$ 0.27
Volatility rate					112.00%
Call option value					$ 0.21
Fair value of stock options					$ 21,004
Stock based compensation expense								$ 21,004
Number of shares granted fully vested common stock option					100,000
2012 Stock Incentive Plan [Member]
Number of shares issued under stock plan							11,500,000
Options exercisable period							10 years

Common Stock Options - Summary

Common Stock Options - Summary of Common Stock Options Outstanding (Details)	12 Months Ended
	Sep. 30, 2018$ / sharesshares
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.16
Range of Exercise Price, Maximum	$ 0.40
Number of Options Outstanding | shares	8,537,500
Weighted Average Remaining Contractual Life	4 years 3 months 8 days
Weighted Average Exercise Price	$ 0.20
Number of Shares Exercisable | shares	8,337,500
Weighted Average Exercise Price Exercisable	$ 0.21

Common Stock Options - Schedule

Common Stock Options - Schedule of Option Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan (Details)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Equity [Abstract]
Average risk-free interest rates	1.36%	0.00%
Average expected life (in years)	5 years 2 months 30 days	0 years
Volatility	112.00%	0.00%

Common Stock Options - Summar_2

Common Stock Options - Summary of Common Stock Options Activity Outstanding (Details) - $ / shares	Jan. 02, 2018	Sep. 30, 2018	Sep. 30, 2017
Equity [Abstract]
Number of Shares Outstanding, Beginning balance		9,290,000	9,291,530
Number of Shares Options expired		(1,220,000)	(1,530)
Number of Shares Options issued		1,005,000
Number of Shares Options exercised	(37,500)	(537,500)
Number of Shares Outstanding, Ending balance		8,537,500	9,290,000
Number of Shares Exercisable		8,337,500
Weighted Average Exercise Price, Outstanding, Beginning		$ 0.23	$ 0.23
Weighted Average Exercise Price, Options expired		(0.42)	(3.30)
Weighted Average Exercise Price, Options issued		0.25
Weighted Average Exercise Price, Options exercised	$ (0.22)	(0.18)
Weighted Average Exercise Price, Outstanding, Ending		0.20	$ 0.23
Weighted Average Exercise Price, Exercisable		$ 0.21

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - $ / shares	Jan. 03, 2018	Jan. 02, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 30, 2017	Sep. 30, 2017
Equity [Abstract]
Number of warrant to purchase of common stock shares	71,428			200,000	300,000
Warrants exercise price per share	$ 0.26		$ 0.29	$ 0.30	$ 0.45	$ 0.26
Number issuance of common stock, shares	34,285	21,000

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details)	12 Months Ended
	Sep. 30, 2018$ / sharesshares
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.1901
Range of Exercise Price, Maximum	$ 0.40
Number of Warrants Outstanding | shares	6,450,462
Weighted Average Remaining Contractual Life	1 year 7 months 24 days
Weighted Average Exercise Price	$ 0.28
Number of Shares Exercisable | shares	6,450,462
Weighted Average Exercise Price, Exercisable	$ 0.28

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grant Under Fixed Option Plan (Details)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Average risk-free interest rates	1.36%	0.00%
Average expected life (in years)	5 years 2 months 30 days	0 years
Volatility	112.00%	0.00%
Warrants [Member]
Average risk-free interest rates	1.56%	1.11%
Average expected life (in years)	3 years	3 years 6 months
Volatility	110.00%	145.00%

Common Stock Warrants - Summa_2

Common Stock Warrants - Summary of Common Stock Warrants Activity Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Equity [Abstract]
Number of Shares, Balance beginning	5,942,422	4,193,136
Number of Shares, Warrants granted	1,079,468	1,749,286
Number of Shares, Warrants exercised	(71,428)
Number of Shares, Warrants expired	(500,000)
Number of Shares, Balance ending	6,450,462	5,942,422
Number of Shares, Exercisable	6,450,462
Weighted Average Exercise Price, Balance, beginning	$ 0.28	$ 0.29
Weighted Average Exercise Price, Warrants granted	0.29	0.26
Weighted Average Exercise Price, Warrants exercised	(0.26)
Weighted Average Exercise Price, Warrants expired	(0.36)
Weighted Average Exercise Price, Balance, ending	0.28	$ 0.28
Weighted Average Exercise Price, Exercisable	$ 0.28

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 191,751	$ 210,907

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payment Under Operating Leases (Details)	Sep. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 48,872
2,019	198,904
2,020	151,283
2,021	50,102
Total	$ 449,161

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Other Income and Expenses [Abstract]
Settlement income on license agreement		$ 250,000
Rental income on subleases	76,800	20,568
Restitution income	28,312	11,500
Other income	$ 105,112	$ 282,068

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2018USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 7,982,500
Operating loss expiration year	2,031

Income Tax - Schedule of Effect

Income Tax - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21.00%	35.00%
State income taxes	0.00%	0.00%
Change in valuation allowance	(21.00%)	(35.00%)
Net effective income tax rate	0.00%	0.00%

Income Tax - Schedule of Deferr

Income Tax - Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 1,676,325	$ 2,531,725
Net deferred tax assets before valuation allowance	1,676,325	2,531,725
Less: Valuation allowance	(1,676,325)	(2,531,725)
Net deferred tax assets

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 25, 2018	Nov. 25, 2018	Nov. 08, 2018	Oct. 30, 2018	Oct. 25, 2018	Nov. 29, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 21, 2018	Nov. 23, 2018	Jan. 03, 2018	Dec. 31, 2017	Dec. 30, 2017
Value of common stock shares issued for services							$ 452,537	$ 246,380
Options exercise price per share							$ 0.25
Volatility rate							112.00%	0.00%
Number of warrant to purchase of common stock shares											71,428	200,000	300,000
Warrants exercise price per share							$ 0.29	$ 0.26			$ 0.26	$ 0.30	$ 0.45
Ten Employees [Member]
Options exercisable period						10 years
Options exercise price per share						$ 0.27
Volatility rate						112.00%
Call option value						$ 0.21
Fair value of stock options						$ 43,057
Subsequent Event [Member]
Number of warrant to purchase of common stock shares									166,667	100,000
Warrants exercise price per share									$ 0.30	$ 0.40
Subsequent Event [Member] | Ten Employees [Member]
Number granted options to purchase shares of common stock	235,000
Options vesting term	12 months
Options exercisable period	10 years
Options exercise price per share	$ 0.13
Volatility rate	107.00%
Call option value	$ 0.1017
Fair value of stock options	$ 35,078
Subsequent Event [Member] | President and CEO [Member]
Number of common stock shares issued for services	46,261
Value of common stock shares issued for services	$ 6,000
Subsequent Event [Member] | Chief Financial Officer [Member]
Number of common stock shares issued for services	115,652
Value of common stock shares issued for services	$ 15,000
Subsequent Event [Member] | Three Consultants [Member]
Number of common stock shares issued for services	150,000	150,000			150,000
Value of common stock shares issued for services	$ 19,455	$ 19,260			$ 23,250
Subsequent Event [Member] | Consultant [Member]
Number of common stock shares issued for services				400,000
Value of common stock shares issued for services				$ 54,120
Subsequent Event [Member] | 8% Senior Secured Convertible Notes [Member] | Two Institutional Investors Member
Debt sold principal amount			$ 500,000
Notes maturity date			Dec. 31, 2020
Notes bear interest rate			8.00%
Notes conversion price per share			$ 0.14